SlideShare une entreprise Scribd logo
1  sur  33
DR AMIT MITTAL
RESIDENT DOCTOR, LLRM MEDICAL
COLLEGE
MEERUT
ECOPHARMACOVIGILANCE
 Active pharmaceutical ingredients represent a group of
emerging environmental contamination.
 It is estimated that worldwide consumption of active
compounds amounts to some 100 000 tons or more per
year.
 Even in trace amounts, they are of great concern due to their
continuous introduction into the environment, their impact on
ecosystem and human and veterinary health is of great
importance
Our home — Earth — is in danger. What is at risk of
being destroyed is not the planet itself, but the
conditions that have made it hospitable for human
beings.
New York Times, July 1 2007
by Al Gore
Ecopharmacovigilance?
Ecopharmacovigilance concerns the adverse
events related to drugs within the ecosystem
with all consequences in humans and other
organisms in the environment
EPV
 The science and activities associated with the detection,
evaluation understanding and prevention of adverse effects
of pharmaceuticals in the environment
 Term first coined by Velo
 Compared to the west EPV in India is in infancy
AIM
 To monitor the adverse effects of pharmaceuticals in the
humans through non therapeutic environmental exposure
 To ensure that significant issues associated with
pharmaceutical in environment are identified and managed
properly.
Pharmacology and Eco-Pharmacology
diffuse i.e. emissions of
medical care units and the
community
aimed, on demand,
controlled
administration
various types of
organisms of different
trophic levels
one type of organismaffected organisms
wanted effects in humans
are often most important
side effects in the
environment
wanted effects, side
effects
wanted effects/
side effects
readily (bio) degradablestabledesirable physico-chemical
properties
an unknown cocktail of
different compounds
one or only a few
compounds at the same
time
number of compounds
administered
Eco-pharmacology
(environment)
Pharmacology
(humans)
SOURCES
 Patient excretion of the drug or its metabolites via the sewage system.
 Direct release from waste water system from manufacturing units.
 Hospital or self disposal of unused, unwanted, expired drugs via trash
or flushing.
 Terrestial deposition
 Sludge application to land,
 Leaching from solid waste landfills
 Irrigation with treated or untreated waste water
Spread of drugs in the environment
 The largest flow of drugs into the environment comes from people who
are under medical treatment.
 Drugs are eliminated from the body either in unchanged form or as
metabolites in faeces and urine and find their way to sewage treatment
plants (STP).
Spread of drugs in the
aqueous phase
 Drugs that break down rapidly will be found close to their sources
and only if they have been released in large amounts.
Example - Acetylsalicylic acid
 Drugs that are both water-soluble and stable will pass through a
treatment plant more or less unchanged and be dispersed in the
surrounding watercourse.
Example - Bezafibrate and other lipid-lowering drugs
 Drugs that are fat-soluble and stable will adsorb to a considerable
extent to sludge particles through the sewage treatment process.
Example - Fluoroquinolones
Spread of drugs in the
drinking water
 The first pharmaceutical substance detected in drinking water was
clofibric acid , found by a german research group in berlin ten years
ago (stan, 1994).
 Since then several drugs (such as bezafibrate, carbamazepine) have
been found in drinking water in germany (ternes, 2001).
The city's sewers each day soaks up its citizens' routines, taking in a steady
stream of products. Toothpaste and shampoo may be harmless enough, but
the waste also collects a wide array of medicines people take. Most drugs are
poorly absorbed and metabolized by the body, so it is not unusual that the
majority of a drug would end up intact in the urine. Because all water goes
through toilets at some point, these artificial compounds, some quite
difficult to break down, can eventually find their way into the city's water
supply—even bottled water.
Nature Medicine 12, 376 - 377
(2006)
Drugs down the drain
EFFECTS ON LONG TERM EXPOSURE
 Chronic toxicity
 Microbial resistance
 Disruption of microbial ecosystem
 Endocrine disruption
 Cytotoxicity
 Mutagenicity
 Teratogenicity
 Growth inhibition
EXAMPLE - 1
 In south-east Asia vultures ingested carcasses of live stock that
has been treated with high doses of diclofenac.
 It is estimated that between 10 to 40 million vultures has been
poisoned
 Three species of gyps vultures are now critically endangered
due to gout & acute and chronic renal failure.
 Government of India has banned diclofenac for veterinary use
EXAMPLE - 2
 Ethinylestradiol has shown to affect the sexual
development of male fish in extremely low concentration in
the laboratory
 Field survey have shown that intersex fish are wide spread
in British river
EXAMPLE - 3
 Sterility of frogs due to traces of oral contraceptives
pills in water became the cause of decrease in
number of frogs
Environmental risk Assessment(ERA)
 Now a regulatory requirement prior to launch of any new drug
 Assess the environmental fate and effects produce by
pharmaceuticals
 Several challenges that has to met if EPV is to effective in
practice like Environment risk management plan
 Environment Risk Management plans (ERMPs) by EU as a
centralized resource to assess and manage the environment
risk of a drug throughout its life cycle which include
information such as
 Physicochemistry
 Human metabolism pharmacokinetics,
 Preclinical toxicology
 Environmental data of the drug
EVALUATION OF EPV
 PEC : PNEC RATIO
 PEC - predicted environmental concentration
 PNEC - the predicted no effect concentration.
 Ratio (PEC:PNEC) - estimate the maximum concentration anticipated
to occur in the environment
 PENC is derived from ecotoxicological test normally in algae, fish.
 If PEC :PNEC < 1, no further information is required
 If > 1 then additional testing required and appropriate risk
management is needed
 According to European guidelines, PEC of pharmaceutical
products in water > 0.01 μg.L−1 before further environmental
risk assessment is necessary
APPROACHES
 Green drug design
 Green chemistry in process development
 Development of biodegradable product
 Minimization of manufacturing emission
 Education on rational use of drugs
 Improved prescribing practice
 Management of unused drug
Short term approach:
effluent treatment
Advanced effluent treatment is still the approach that is favoured
despite its increasingly visible technical and economical limitations and
unsatisfactory performance .
 This approach is probably not sustainable .
Fate of pharmaceuticals in treatment plants (STPs)
Carbamazepine
Clarithromycin
Erythromycin
Estrone
Lincomycin
Spiramycin
Removal rate: 0%
Amoxycillin
Ciprofloxacin
Enalapril
Ibuprofen
Ofloxacin
Removal rate:
30-60%
Atenolol
Bezafibrate
Clofibric acid
Furosemide
Diazepam
Removal rate;
10-30%
Hydrochlorothiazide
Ranitidine
Sulphamethoxazole
Removal rate:
variable
Long term approach:
green pharmacy
Green Chemistry ?
• Green chemistry is the design of
chemical products and processes that
reduce or eliminate the use and
generation of hazardous substances
Green Pharmacy aims at zero pharmaceutical waste in
our environment
Daughton proposed the need for “green
pharmacy,” where the life cycle of pharmaceuticals,
from “cradle-to-grave,” including synthesis from
raw materials, production of products, transportation,
storage, deliveries, usage, and disposal, are
appropriately assessed, anticipated, and managed.
The most simple and direct way to apply green chemistry in pharmaceuticals
is to utilize eco-friendly, non-hazardous, reproducible and efficient
solvents and catalysts in synthesis of drug molecules, drug intermediates
and in researches involving synthetic chemistry
New compounds are effective, efficient, and
readily degradable in the environment
Long Term Risk Management:
Green Pharmacy
identification structures essential for
• efficacy
• (bio)degradability
Modification of Structure
Changes Properties
OH
Benzene:
not biodegradable
cancergenic,
not bactericidal
Phenol:
readily biodgradable
not cancerogenic
bactericidal
KEY RECOMMENDATION ON EPV
IMPLEMENTATION
 BUILDING PERFECT LAWS & REGULATION SYSTEM
 DEFINING THE EVALUATION INDEX
 CONTINUING THE CLINICAL RATIONAL MEDICATION
 TAKE BACK POLICY
 POPULARIZING THE CONCEPT OF EPV
 STRENGTHENING THE POLICY GUIDED & SCIENTIFIC
RESEARCH OF EPV IN PHARMA FIRMS & ACADEMIA
ECOPHARMACOVIGILANCE

Contenu connexe

Tendances

Quality Use of Medicines
Quality Use of MedicinesQuality Use of Medicines
Quality Use of Medicines
kbaskett
 

Tendances (20)

Detection, reporting and management of adverse events
Detection, reporting and management of adverse eventsDetection, reporting and management of adverse events
Detection, reporting and management of adverse events
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting System
 
Safety monitoring in clinical trails
Safety monitoring in clinical trailsSafety monitoring in clinical trails
Safety monitoring in clinical trails
 
Pharmacoepideiology
PharmacoepideiologyPharmacoepideiology
Pharmacoepideiology
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
ADR AND ITS MONITORING
ADR  AND  ITS MONITORING ADR  AND  ITS MONITORING
ADR AND ITS MONITORING
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Drug Utilization review
Drug Utilization review Drug Utilization review
Drug Utilization review
 
Pharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistPharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacist
 
Assignment on pharmacovigilance
Assignment on pharmacovigilanceAssignment on pharmacovigilance
Assignment on pharmacovigilance
 
Pre Clinical Studies
Pre Clinical StudiesPre Clinical Studies
Pre Clinical Studies
 
Establishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance ProgrammeEstablishment of Pharmacovigilance Programme
Establishment of Pharmacovigilance Programme
 
Quality Use of Medicines
Quality Use of MedicinesQuality Use of Medicines
Quality Use of Medicines
 
Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)Regulatory terminologies used in PV (Pharmacovigilance)
Regulatory terminologies used in PV (Pharmacovigilance)
 
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’SSEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
SEVERITY AND SERIOUSNESS ASSESSMENT OF ADR’S
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
Roles and responsibilities in clinical trials
Roles and responsibilities in clinical trialsRoles and responsibilities in clinical trials
Roles and responsibilities in clinical trials
 
Drug safety evaluation in clinical trial
Drug safety evaluation in clinical trialDrug safety evaluation in clinical trial
Drug safety evaluation in clinical trial
 

En vedette

Vasopressin receptor antagonist and therapeutic potential
Vasopressin receptor antagonist and therapeutic potentialVasopressin receptor antagonist and therapeutic potential
Vasopressin receptor antagonist and therapeutic potential
Dr Amit Mittal
 
Biogeochemical cycles
Biogeochemical cyclesBiogeochemical cycles
Biogeochemical cycles
Ikhwanul Azmi
 
The Translational Medicine
The Translational MedicineThe Translational Medicine
The Translational Medicine
Joanne Luciano
 
Factors affecting biotransformation of drugs
Factors affecting biotransformation of drugsFactors affecting biotransformation of drugs
Factors affecting biotransformation of drugs
vincyv88
 
Environmental impact assessment m5
Environmental impact assessment m5Environmental impact assessment m5
Environmental impact assessment m5
Bibhabasu Mohanty
 
Environment ppt
Environment pptEnvironment ppt
Environment ppt
Urvil Shah
 

En vedette (15)

Vasopressin receptor antagonist and therapeutic potential
Vasopressin receptor antagonist and therapeutic potentialVasopressin receptor antagonist and therapeutic potential
Vasopressin receptor antagonist and therapeutic potential
 
Ecopharmacology
EcopharmacologyEcopharmacology
Ecopharmacology
 
Why pick on pharmaceuticals as an environmental "problem"(setac basle 2014)
Why pick on pharmaceuticals as an environmental "problem"(setac basle 2014)Why pick on pharmaceuticals as an environmental "problem"(setac basle 2014)
Why pick on pharmaceuticals as an environmental "problem"(setac basle 2014)
 
Modifying the environment for a patient with low vision
Modifying the environment for a patient with low visionModifying the environment for a patient with low vision
Modifying the environment for a patient with low vision
 
Biogeochemical cycles
Biogeochemical cyclesBiogeochemical cycles
Biogeochemical cycles
 
Ecology
EcologyEcology
Ecology
 
Biogeochemical Cycles
Biogeochemical CyclesBiogeochemical Cycles
Biogeochemical Cycles
 
Biogeochemical cycles
Biogeochemical cyclesBiogeochemical cycles
Biogeochemical cycles
 
The Translational Medicine
The Translational MedicineThe Translational Medicine
The Translational Medicine
 
Factors affecting biotransformation of drugs
Factors affecting biotransformation of drugsFactors affecting biotransformation of drugs
Factors affecting biotransformation of drugs
 
Biogeochemical cycles
Biogeochemical cyclesBiogeochemical cycles
Biogeochemical cycles
 
Environmental impact assessment m5
Environmental impact assessment m5Environmental impact assessment m5
Environmental impact assessment m5
 
Biogeochemical cycles
Biogeochemical cyclesBiogeochemical cycles
Biogeochemical cycles
 
Soil microbiology
Soil microbiologySoil microbiology
Soil microbiology
 
Environment ppt
Environment pptEnvironment ppt
Environment ppt
 

Similaire à ECOPHARMACOVIGILANCE

Lab #11 – EcotoxicologyPrelab DiscussionT.docx
Lab #11 – EcotoxicologyPrelab DiscussionT.docxLab #11 – EcotoxicologyPrelab DiscussionT.docx
Lab #11 – EcotoxicologyPrelab DiscussionT.docx
croysierkathey
 
3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)
Teleosis Institute
 

Similaire à ECOPHARMACOVIGILANCE (20)

Environmental Pharmacology
Environmental PharmacologyEnvironmental Pharmacology
Environmental Pharmacology
 
Environmental pharmacology
Environmental pharmacology Environmental pharmacology
Environmental pharmacology
 
2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)2.5. PharmEcoVigilance (Ruhoy)
2.5. PharmEcoVigilance (Ruhoy)
 
ERHS220 poster
ERHS220 posterERHS220 poster
ERHS220 poster
 
Lab #11 – EcotoxicologyPrelab DiscussionT.docx
Lab #11 – EcotoxicologyPrelab DiscussionT.docxLab #11 – EcotoxicologyPrelab DiscussionT.docx
Lab #11 – EcotoxicologyPrelab DiscussionT.docx
 
Antibiotic waste water in hospital effluents
Antibiotic waste water in hospital effluentsAntibiotic waste water in hospital effluents
Antibiotic waste water in hospital effluents
 
Pesticides classification and maximum residue limits in food
Pesticides classification and maximum residue limits in foodPesticides classification and maximum residue limits in food
Pesticides classification and maximum residue limits in food
 
Ecopharmacology
EcopharmacologyEcopharmacology
Ecopharmacology
 
Pesticides classification and maximum residue limits in food.Renamed_0001.pdf
Pesticides classification and maximum residue limits in food.Renamed_0001.pdfPesticides classification and maximum residue limits in food.Renamed_0001.pdf
Pesticides classification and maximum residue limits in food.Renamed_0001.pdf
 
D032019027
D032019027D032019027
D032019027
 
2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)
2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)
2.2. Significance of Long-Term Exposure to Multiple APIs (Ruhoy)
 
Emerging Contaminant Threats and the Great Lakes
Emerging Contaminant Threats and the Great LakesEmerging Contaminant Threats and the Great Lakes
Emerging Contaminant Threats and the Great Lakes
 
Presence of Pesticides in Fruits and vegetables
Presence of Pesticides in Fruits and vegetables Presence of Pesticides in Fruits and vegetables
Presence of Pesticides in Fruits and vegetables
 
Environmental issues pharmaceuticals in our dringing water
Environmental issues pharmaceuticals in our dringing waterEnvironmental issues pharmaceuticals in our dringing water
Environmental issues pharmaceuticals in our dringing water
 
Ozone wastewater treatment
Ozone wastewater treatmentOzone wastewater treatment
Ozone wastewater treatment
 
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
2.6. Reducing Unused Pharmaceuticals: Conclusion (Ruhoy)
 
3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)3.5. Facts About Disposal in the U.S. (Kreisberg)
3.5. Facts About Disposal in the U.S. (Kreisberg)
 
Emerging contaminants in surface and Drainage Water By Shiv
Emerging contaminants in surface and Drainage Water By ShivEmerging contaminants in surface and Drainage Water By Shiv
Emerging contaminants in surface and Drainage Water By Shiv
 
Study on the environmental risks of medicinal products ppt
Study on the environmental risks of medicinal products pptStudy on the environmental risks of medicinal products ppt
Study on the environmental risks of medicinal products ppt
 
20060126.ppt
20060126.ppt20060126.ppt
20060126.ppt
 

ECOPHARMACOVIGILANCE

  • 1. DR AMIT MITTAL RESIDENT DOCTOR, LLRM MEDICAL COLLEGE MEERUT ECOPHARMACOVIGILANCE
  • 2.  Active pharmaceutical ingredients represent a group of emerging environmental contamination.  It is estimated that worldwide consumption of active compounds amounts to some 100 000 tons or more per year.  Even in trace amounts, they are of great concern due to their continuous introduction into the environment, their impact on ecosystem and human and veterinary health is of great importance
  • 3. Our home — Earth — is in danger. What is at risk of being destroyed is not the planet itself, but the conditions that have made it hospitable for human beings. New York Times, July 1 2007 by Al Gore
  • 4. Ecopharmacovigilance? Ecopharmacovigilance concerns the adverse events related to drugs within the ecosystem with all consequences in humans and other organisms in the environment
  • 5. EPV  The science and activities associated with the detection, evaluation understanding and prevention of adverse effects of pharmaceuticals in the environment  Term first coined by Velo  Compared to the west EPV in India is in infancy
  • 6. AIM  To monitor the adverse effects of pharmaceuticals in the humans through non therapeutic environmental exposure  To ensure that significant issues associated with pharmaceutical in environment are identified and managed properly.
  • 7. Pharmacology and Eco-Pharmacology diffuse i.e. emissions of medical care units and the community aimed, on demand, controlled administration various types of organisms of different trophic levels one type of organismaffected organisms wanted effects in humans are often most important side effects in the environment wanted effects, side effects wanted effects/ side effects readily (bio) degradablestabledesirable physico-chemical properties an unknown cocktail of different compounds one or only a few compounds at the same time number of compounds administered Eco-pharmacology (environment) Pharmacology (humans)
  • 8. SOURCES  Patient excretion of the drug or its metabolites via the sewage system.  Direct release from waste water system from manufacturing units.  Hospital or self disposal of unused, unwanted, expired drugs via trash or flushing.  Terrestial deposition  Sludge application to land,  Leaching from solid waste landfills  Irrigation with treated or untreated waste water
  • 9.
  • 10. Spread of drugs in the environment  The largest flow of drugs into the environment comes from people who are under medical treatment.  Drugs are eliminated from the body either in unchanged form or as metabolites in faeces and urine and find their way to sewage treatment plants (STP).
  • 11. Spread of drugs in the aqueous phase  Drugs that break down rapidly will be found close to their sources and only if they have been released in large amounts. Example - Acetylsalicylic acid  Drugs that are both water-soluble and stable will pass through a treatment plant more or less unchanged and be dispersed in the surrounding watercourse. Example - Bezafibrate and other lipid-lowering drugs  Drugs that are fat-soluble and stable will adsorb to a considerable extent to sludge particles through the sewage treatment process. Example - Fluoroquinolones
  • 12. Spread of drugs in the drinking water  The first pharmaceutical substance detected in drinking water was clofibric acid , found by a german research group in berlin ten years ago (stan, 1994).  Since then several drugs (such as bezafibrate, carbamazepine) have been found in drinking water in germany (ternes, 2001).
  • 13. The city's sewers each day soaks up its citizens' routines, taking in a steady stream of products. Toothpaste and shampoo may be harmless enough, but the waste also collects a wide array of medicines people take. Most drugs are poorly absorbed and metabolized by the body, so it is not unusual that the majority of a drug would end up intact in the urine. Because all water goes through toilets at some point, these artificial compounds, some quite difficult to break down, can eventually find their way into the city's water supply—even bottled water. Nature Medicine 12, 376 - 377 (2006) Drugs down the drain
  • 14. EFFECTS ON LONG TERM EXPOSURE  Chronic toxicity  Microbial resistance  Disruption of microbial ecosystem  Endocrine disruption  Cytotoxicity  Mutagenicity  Teratogenicity  Growth inhibition
  • 15. EXAMPLE - 1  In south-east Asia vultures ingested carcasses of live stock that has been treated with high doses of diclofenac.  It is estimated that between 10 to 40 million vultures has been poisoned  Three species of gyps vultures are now critically endangered due to gout & acute and chronic renal failure.  Government of India has banned diclofenac for veterinary use
  • 16. EXAMPLE - 2  Ethinylestradiol has shown to affect the sexual development of male fish in extremely low concentration in the laboratory  Field survey have shown that intersex fish are wide spread in British river
  • 17. EXAMPLE - 3  Sterility of frogs due to traces of oral contraceptives pills in water became the cause of decrease in number of frogs
  • 18. Environmental risk Assessment(ERA)  Now a regulatory requirement prior to launch of any new drug  Assess the environmental fate and effects produce by pharmaceuticals  Several challenges that has to met if EPV is to effective in practice like Environment risk management plan
  • 19.  Environment Risk Management plans (ERMPs) by EU as a centralized resource to assess and manage the environment risk of a drug throughout its life cycle which include information such as  Physicochemistry  Human metabolism pharmacokinetics,  Preclinical toxicology  Environmental data of the drug
  • 20. EVALUATION OF EPV  PEC : PNEC RATIO  PEC - predicted environmental concentration  PNEC - the predicted no effect concentration.  Ratio (PEC:PNEC) - estimate the maximum concentration anticipated to occur in the environment  PENC is derived from ecotoxicological test normally in algae, fish.
  • 21.  If PEC :PNEC < 1, no further information is required  If > 1 then additional testing required and appropriate risk management is needed  According to European guidelines, PEC of pharmaceutical products in water > 0.01 μg.L−1 before further environmental risk assessment is necessary
  • 22. APPROACHES  Green drug design  Green chemistry in process development  Development of biodegradable product  Minimization of manufacturing emission  Education on rational use of drugs  Improved prescribing practice  Management of unused drug
  • 23. Short term approach: effluent treatment Advanced effluent treatment is still the approach that is favoured despite its increasingly visible technical and economical limitations and unsatisfactory performance .  This approach is probably not sustainable .
  • 24. Fate of pharmaceuticals in treatment plants (STPs) Carbamazepine Clarithromycin Erythromycin Estrone Lincomycin Spiramycin Removal rate: 0% Amoxycillin Ciprofloxacin Enalapril Ibuprofen Ofloxacin Removal rate: 30-60% Atenolol Bezafibrate Clofibric acid Furosemide Diazepam Removal rate; 10-30% Hydrochlorothiazide Ranitidine Sulphamethoxazole Removal rate: variable
  • 26. Green Chemistry ? • Green chemistry is the design of chemical products and processes that reduce or eliminate the use and generation of hazardous substances Green Pharmacy aims at zero pharmaceutical waste in our environment
  • 27. Daughton proposed the need for “green pharmacy,” where the life cycle of pharmaceuticals, from “cradle-to-grave,” including synthesis from raw materials, production of products, transportation, storage, deliveries, usage, and disposal, are appropriately assessed, anticipated, and managed.
  • 28. The most simple and direct way to apply green chemistry in pharmaceuticals is to utilize eco-friendly, non-hazardous, reproducible and efficient solvents and catalysts in synthesis of drug molecules, drug intermediates and in researches involving synthetic chemistry
  • 29. New compounds are effective, efficient, and readily degradable in the environment Long Term Risk Management: Green Pharmacy identification structures essential for • efficacy • (bio)degradability
  • 30. Modification of Structure Changes Properties OH Benzene: not biodegradable cancergenic, not bactericidal Phenol: readily biodgradable not cancerogenic bactericidal
  • 31.
  • 32. KEY RECOMMENDATION ON EPV IMPLEMENTATION  BUILDING PERFECT LAWS & REGULATION SYSTEM  DEFINING THE EVALUATION INDEX  CONTINUING THE CLINICAL RATIONAL MEDICATION  TAKE BACK POLICY  POPULARIZING THE CONCEPT OF EPV  STRENGTHENING THE POLICY GUIDED & SCIENTIFIC RESEARCH OF EPV IN PHARMA FIRMS & ACADEMIA